{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT03343782",
      "OrgStudyIdInfo": {
        "OrgStudyId": "VinmecRISCGT70"
      },
      "Organization": {
        "OrgFullName": "Vinmec Research Institute of Stem Cell and Gene Technology",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Outcomes of Expanded Autologous Bone Marrow-derived Mesenchymal Stem Cells Therapy in Type II Diabetes",
      "OfficialTitle": "Outcomes of Expanded Autologous Bone Marrow-derived Mesenchymal Stem Cells Therapy in Type 2 Diabetes",
      "Acronym": "ASD2"
    },
    "StatusModule": {
      "StatusVerifiedDate": "June 2021",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "November 1, 2017",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "August 1, 2019",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "August 1, 2019",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "November 12, 2017",
      "StudyFirstSubmitQCDate": "November 12, 2017",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "November 17, 2017",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "June 14, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "June 18, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Vinmec Research Institute of Stem Cell and Gene Technology",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "The purpose of this study is to evaluate the safety and effectiveness of autologous bone marrow-derived mesenchymal stem cells transplantation in the treatment of type 2 diabetes mellitus",
      "DetailedDescription": "Bone marrow-derived mesenchymal stem cells have the immunosuppressive effect and secrete a variety of cytokines, improve the microenvironment of diabetic patients, targeting insulin resistance tissue, ameliorate the metabolic disorder of islet damage, protect and regeneration of the islet beta cells; reduce high blood sugar.The purpose of this study is to evaluate the safety and effectiveness of autologous bone marrow-derived mesenchymal stem cells transplantation in treatment 30 patients with type 2 diabetes mellitus at Vinmec International Hospital, Hanoi, Vietnam"
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Type 2 Diabetes Mellitus"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Diabetes",
          "BM mesenchymal stem cell"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "30",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Stem cell transplantation",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Intervention: 30 patients will be transplanted autologous bone marrow-derived mesenchymal stem cells and undergoing 2 treatment with 6 months interval",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Combination Product: Expanded autologous bone marrow-derived mesenchymal stem cell"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Combination Product",
            "InterventionName": "Expanded autologous bone marrow-derived mesenchymal stem cell",
            "InterventionDescription": "Collect bone marrow from lilac crest using local anaesthetic and syringe collection. Mesenchymal stem cell will be isolated, expanded and characterized in vitro under the GMP- grade procedure",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Stem cell transplantation"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Insulin dose",
            "PrimaryOutcomeDescription": "Reduction of insulin dose requirement by â‰¥50% in both groups",
            "PrimaryOutcomeTimeFrame": "up to the 12-month period following treatment"
          },
          {
            "PrimaryOutcomeMeasure": "Adverse events",
            "PrimaryOutcomeDescription": "Number of adverse events in both groups",
            "PrimaryOutcomeTimeFrame": "up to the 12-month period following treatment"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Hemoglobin A1c (HbA1c) level",
            "SecondaryOutcomeDescription": "Improvement of HbA1c level as compared to baseline between two groups",
            "SecondaryOutcomeTimeFrame": "up to the 12-month period following treatment"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nMales and females from 18 years and above.\nHemoglobin A1c (HbA1c) is ranged from 7.5% to 9% at baseline.\nType 2 diabetes duration 5 years or more.\nBefore the screening, joint or combined with insulin, oral medications to treat more than 3 months.\nWho signed the informed consent form.\n\nExclusion Criteria:\n\nType 1 diabetes.\nChronic disease or severe disease, including cancer, severe heart disease, kidney disease, liver disease, etc.\nAccording to the medical doctor's judgement, may endanger the safety of the subjects",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Vinmec Research Institute of Stem Cell and Gene Technology",
            "LocationCity": "Hanoi",
            "LocationZip": "10000",
            "LocationCountry": "Vietnam"
          }
        ]
      }
    },
    "ReferencesModule": {
      "ReferenceList": {
        "Reference": [
          {
            "ReferencePMID": "34080789",
            "ReferenceType": "result",
            "ReferenceCitation": "Nguyen LT, Hoang DM, Nguyen KT, Bui DM, Nguyen HT, Le HTA, Hoang VT, Bui HTH, Dam PTM, Hoang XTA, Ngo ATL, Le HM, Phung NY, Vu DM, Duong TT, Nguyen TD, Ha LT, Bui HTP, Nguyen HK, Heke M, Bui AV. Type 2 diabetes mellitus duration and obesity alter the efficacy of autologously transplanted bone marrow-derived mesenchymal stem/stromal cells. Stem Cells Transl Med. 2021 Sep;10(9):1266-1278. doi: 10.1002/sctm.20-0506. Epub 2021 Jun 3."
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "No"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000003920",
            "ConditionMeshTerm": "Diabetes Mellitus"
          },
          {
            "ConditionMeshId": "D000003924",
            "ConditionMeshTerm": "Diabetes Mellitus, Type 2"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000044882",
            "ConditionAncestorTerm": "Glucose Metabolism Disorders"
          },
          {
            "ConditionAncestorId": "D000008659",
            "ConditionAncestorTerm": "Metabolic Diseases"
          },
          {
            "ConditionAncestorId": "D000004700",
            "ConditionAncestorTerm": "Endocrine System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M6267",
            "ConditionBrowseLeafName": "Diabetes Mellitus",
            "ConditionBrowseLeafAsFound": "Diabetes",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M6271",
            "ConditionBrowseLeafName": "Diabetes Mellitus, Type 2",
            "ConditionBrowseLeafAsFound": "Type 2 Diabetes",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M10791",
            "ConditionBrowseLeafName": "Metabolic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M24556",
            "ConditionBrowseLeafName": "Glucose Metabolism Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M7014",
            "ConditionBrowseLeafName": "Endocrine System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC18",
            "ConditionBrowseBranchName": "Nutritional and Metabolic Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC19",
            "ConditionBrowseBranchName": "Gland and Hormone Related Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M3259",
            "InterventionBrowseLeafName": "Anesthetics",
            "InterventionBrowseLeafRelevance": "low"
          },
          {
            "InterventionBrowseLeafId": "M3261",
            "InterventionBrowseLeafName": "Anesthetics, Local",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "CNSDep",
            "InterventionBrowseBranchName": "Central Nervous System Depressants"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}